Related Experiment Video
Updated: Apr 25, 2026

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
Acromegaly and Cardiovascular Disease: Mechanisms, Clinical Impact, and Evolving Management
Marta Araujo-Castro1,2, Pedro Marques3, Luis Miguel Cardoso4
1Endocrinology & Nutrition Department. Hospital Universitario Ramón y Cajal. Madrid, Spain.
Insights
Acromegaly significantly increases cardiovascular disease risk, impacting life expectancy. Early diagnosis and management of heart complications are crucial for improving outcomes in patients with growth hormone excess.
Area of Science:
- Endocrinology
- Cardiology
- Internal Medicine
Background:
- Acromegaly, caused by excess growth hormone and insulin-like growth factor 1, is linked to severe cardiovascular complications.
- These complications are a primary cause of reduced life expectancy in acromegaly patients.
Purpose of the Study:
- To review the prevalence, mechanisms, diagnosis, and management of cardiovascular complications in acromegaly.
- To highlight the importance of early recognition and targeted treatment.
Main Methods:
- Literature review examining cardiovascular disturbances associated with acromegaly.
- Analysis of the impact of growth hormone and IGF-1 excess on cardiovascular health.
- Review of diagnostic strategies and therapeutic options.
Main Results:
- Excess GH and IGF-1 cause structural heart changes, arrhythmias, vascular dysfunction, and traditional risk factors like hypertension, diabetes, and dyslipidemia.
- While acromegaly treatments can reverse some cardiovascular alterations, managing comorbid conditions remains vital for cardiometabolic risk.
- Advances improve survival, but knowledge gaps persist in preventing/reversing cardiovascular damage.
Conclusions:
- Multidisciplinary care and individualized risk assessment are essential for managing acromegaly-related cardiovascular disease.
- Effective management requires addressing both hormonal excess and associated comorbidities.
- Further research is needed to optimize prevention and treatment strategies.
Abstract:
Cardiovascular disease is one of the most common and serious complications of acromegaly and a leading contributor to reduced life expectancy in affected individuals. This review examines the prevalence, mechanisms, diagnosis, and management of cardiovascular complications in patients with acromegaly. Growth hormone and insulin-like growth factor 1 excess promotes a range of cardiovascular disturbances, including structural heart changes, arrhythmias, vascular dysfunction, and an increased burden of traditional cardiovascular risk factors such as hypertension, diabetes, and dyslipidemia. Early recognition and targeted treatment of these complications are critical to reducing cardiovascular morbidity and mortality. While surgery and medical therapies for acromegaly aimed at normalizing hormone levels may lead to partial or full reversal of some cardiovascular alterations, many patients require continued management of comorbid conditions to control their overall cardiometabolic risk. Advances in diagnostic strategies and therapeutic options have contributed to improved survival, yet gaps remain in our understanding of how best to prevent or reverse cardiovascular damage in this population. Multidisciplinary care and individualized risk assessment are essential components of modern acromegaly management.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Coronary Artery Disease I: Introduction
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Aortic Regurgitation III: Medical Management
Hypertension III: Clinical Manifestations and Diagnostic Studies
